KAT2A and obesity disorder: Indeed, several small molecule that inhibit GCN5 (i.e. MB‐3) have been discovered and already taken into consideration for the treatment of different pathologies associated with GCN5 dysregulation like type 2 diabetes, insulin resistance, metabolic disease and syndrome, dyslipidaemia, obesity or overweight, neurodegenerative diseases, heart failure, muscle diseases and improvement of exercise endurance capacity.39, 40